Medicine and Dentistry
Overall Survival
100%
Progression Free Survival
82%
Rituximab
62%
Diffuse Large B-Cell Lymphoma
62%
Diseases
49%
B-Cell Lymphoma
47%
Mantle Cell Lymphoma
46%
Non-Hodgkin Lymphoma
44%
Chimeric Antigen Receptor T-Cell Immunotherapy
38%
B Cell
37%
MALT Lymphoma
32%
Malignant Neoplasm
28%
Hematopoietic Cell
28%
Cohort Analysis
27%
Classical Hodgkin Lymphoma
26%
Cell Transplantation
24%
Follicular Lymphoma
22%
Hodgkin's Lymphoma
21%
Central Nervous System
21%
Burkitt's Lymphoma
20%
Survival Rate
20%
Cyclophosphamide
19%
Doxorubicin
18%
Vincristine
17%
Cachexia
17%
Clinical Trial
16%
Prognostic Factor
16%
Pembrolizumab
15%
Venetoclax
14%
Aggressive Lymphoma
14%
Lymphoma Cell
14%
Cancer
14%
Drug Megadose
13%
Chemoimmunotherapy
13%
Prednisone
13%
Hazard Ratio
13%
Comorbidity
13%
Retrospective Study
12%
Large-Cell Lymphoma
12%
Allograft
12%
CAR T-cell therapy
12%
Cyclophosphamide Plus Doxorubicin Plus Etoposide Plus Prednisolone Plus Rituximab Plus Vincristine
12%
Methotrexate
12%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
11%
Chimeric Antigen Receptor T-Cell
11%
Primary Central Nervous System Lymphoma
10%
Etoposide
10%
Radiation Therapy
10%
Neoplasm
10%
Adverse Event
9%
Keyphrases
Overall Survival
81%
Progression-free Survival
64%
Relapsed or Refractory
54%
Diffuse Large B-cell Lymphoma (DLBCL)
51%
Mantle Cell Lymphoma
48%
Rituximab
45%
Chimeric Antigen Receptor T-cell Therapy
42%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
42%
Lymphoma Patients
40%
Lymphoma
31%
Marginal Zone Lymphoma
30%
Double-hit Lymphoma
28%
Follicular Lymphoma
25%
Multicenter Cohort Study
25%
Primary Central Nervous System Lymphoma (PCNSL)
23%
Non-Hodgkin Lymphoma
22%
Overall Response Rate
22%
Complete Response
22%
Classical Hodgkin Lymphoma
21%
Confidence Interval
20%
Older Patients
20%
Hodgkin Lymphoma
20%
Survival Outcomes
20%
Burkitt Lymphoma
19%
Cachexia
19%
B-cell Lymphoma
19%
Prognostic Factors
18%
Large B-cell Lymphoma
17%
Cyclophosphamide
16%
Clinical Outcomes
16%
High Risk
16%
Frontline Therapy
15%
Newly Diagnosed
15%
Lymphoma Cells
15%
Pembrolizumab
15%
Aggressive B-cell Lymphoma
15%
Double Hit
15%
Subsequent Therapy
14%
Primary Treatment Failure
14%
Disease Progression
14%
Doxorubicin
14%
Retrospective Analysis
14%
Aggressive Lymphoma
14%
Central Nervous System Involvement
13%
Venetoclax
13%
Overall Survival Rate
13%
Rituximab Era
13%
Aggressive B-cell non-Hodgkin Lymphoma
13%
Immunochemotherapy
13%
Cancer Patients
13%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
54%
Progression Free Survival
52%
Rituximab
49%
Diseases
36%
Mantle Cell Lymphoma
36%
Malignant Neoplasm
35%
Chimeric Antigen Receptor
29%
Chemotherapy
28%
B Cell Lymphoma
25%
Diffuse Large B Cell Lymphoma
25%
Nonhodgkin Lymphoma
23%
Burkitt's Lymphoma
18%
Cachexia
18%
Cohort Study
18%
Marginal Zone Lymphoma
17%
Venetoclax
15%
Doxorubicin
14%
Vincristine
14%
Cyclophosphamide
13%
Cyclophosphamide Plus Doxorubicin Plus Etoposide Plus Prednisolone Plus Rituximab Plus Vincristine
13%
Hodgkin Disease
12%
Neoplasm
12%
Acute Myeloid Leukemia
11%
Methotrexate
11%
Survival Rate
11%
Prednisone
10%
Combination Therapy
10%
Follicular Lymphoma
10%
Hematologic Malignancy
10%
Adverse Event
10%
Clinical Trial
9%
Brentuximab Vedotin
8%
Lenalidomide
8%
Immunotherapy
7%
Lactate Dehydrogenase
7%
Remission
7%
Cytarabine
6%
Immunoglobulin
6%
Neutropenia
6%
Comorbidity
6%
Primary Central Nervous System Lymphoma
6%
Idelalisib
5%
Thrombocytopenia
5%
Minimal Residual Disease
5%
Somatomedin C
5%
HIV
5%
Etoposide
5%
Anthracycline
5%
Cytotoxic Chemotherapy
5%
Cardiotoxicity
5%